FDA Brief

Warning letters Food

FDA warning letter to

Diamond-Herpanacine of PA, Inc.

LowIssued Jan 22Posted May 5Human Foods Program

FDA says Diamond-Herpanacine supplement claims make its eye and skin products unapproved drugs.

What happened

FDA reviewed the company’s website in September 2025 and its Facebook page, which directs consumers to the website. FDA found claims that Diamond Eye Health and Herpanacine Skin Support treat or prevent diseases such as eye degeneration, herpes, eczema, and other skin conditions, plus customer testimonials about eye problems.

What FDA found

  1. The website and Facebook claims show the products are intended to cure, mitigate, treat, or prevent disease, which makes them drugs.

    section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The products are not generally recognized as safe and effective for those uses, so they are “new drugs” (unapproved drugs).

    section 201(p) of the Act [21 U.S.C. 321(p)]
  3. The new drugs are offered for sale without prior FDA approval.

    sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]
  4. The products are misbranded because they lack adequate directions for use; the claimed diseases cannot be safely self-diagnosed or treated without a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]
  5. Shipping these misbranded drugs in interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to write within 15 working days of receipt describing the specific steps taken to correct the violations and prevent recurrence, or to explain why it believes the products are not violating the law.

Who should pay attention

  • dietary supplement brands making disease-treatment claims
  • companies selling supplements for eye or skin conditions
  • retailers and marketplaces listing supplement products with health claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk